GKOS stock forecast, quote, news & analysis
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases... Show more
Why Glaukos Corporation (GKOS) Is Up +18% in the Last 30 Days
Key Takeaways
- GKOS stock surged +18% over the past 30 days, propelled by the commercial launch of Epioxa for keratoconus treatment and securing a permanent J-code for reimbursement.
- Over the past quarter, shares rose a modest +1%, reflecting stabilization after Q4 earnings that showed strong revenue growth despite an EPS miss.
- Analyst upgrades and raised price targets from firms like Citi and Mizuho boosted sentiment amid expanding product portfolio in ophthalmology.
- Core drivers include robust U.S. glaucoma franchise growth and new corneal therapy adoption, offsetting post-earnings volatility.
- Market trends in medtech innovation and favorable reimbursement news supported the recent price movement.
Glaukos Corporation (GKOS) Company Overview and Market Position
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its core business model centers on innovative, minimally invasive devices and dropless pharmaceutical therapies that improve patient outcomes and reduce surgical burdens in ophthalmology. Operating in the competitive medtech sector, Glaukos holds a strong position with its iStent platform as a leader in glaucoma treatment, complemented by expanding corneal and retinal pipelines. These fundamentals, including sustained revenue from U.S. commercial platforms and new product momentum, underpin recent stock price resilience amid sector demand for advanced eye care solutions.
Glaukos Corporation (GKOS) Stock Price Performance: Last 30 Days vs. Quarter
The latest available closing price for GKOS stands at approximately $122, marking a sharp +18% gain from around $103 thirty days prior. This upward trend was trend-driven with notable volatility around product announcements, transitioning from range-bound early in the period to steady gains. Over the past quarter, the stock advanced +1% from near $120, exhibiting relatively flat performance overall—steady post-earnings with minor fluctuations amid broader market trends. The movement reflects a recovery pattern, supported by positive catalysts outweighing initial profit-taking.
What Drove GKOS Stock Price in the Last 30 Days
The +18% rally in GKOS stock over the past 30 days was primarily fueled by the commercial launch of Epioxa HD/Epioxa, a dropless therapy for keratoconus—a corneal disorder affecting vision clarity. This milestone expanded Glaukos' addressable market beyond glaucoma, with announcements on March 19 and 20 sparking initial buying interest. Momentum accelerated with the April 15-16 securing of a permanent J-code (a reimbursement billing code from CMS), enhancing payer coverage and adoption potential, directly lifting shares. Analyst actions amplified the move, including Mizuho's Buy rating on April 13 and Citi raising its price target to $135 from $125 on April 7, signaling confidence in pipeline execution. Positive market sentiment toward ophthalmology innovation, coupled with Glaukos' strong U.S. sales execution, connected these developments to sustained price appreciation.
What Drove GKOS Stock Performance Over the Last Quarter
GKOS shares posted a modest +1% gain over the quarter, balancing Q4 2025 earnings dynamics with emerging product catalysts. Glaukos reported 36-38% net sales growth in the period, driven by U.S. glaucoma franchise strength and international expansion, alongside ambitious 2026 guidance that initially propelled a 13% post-earnings jump. However, an adjusted EPS miss of -28 cents versus expectations contributed to a subsequent pullback of about 15% in the following weeks, tempering gains. Broader industry tailwinds in medtech reimbursement and demand for minimally invasive therapies provided support, while institutional interest and competitive positioning in ophthalmology sustained flat-to-upward trajectory. Macro factors like stable healthcare spending offset volatility, with Epioxa developments late in the quarter reinforcing cumulative positive impact.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds that analyze and trade thousands of tickers across various markets. These curated bots employ diverse strategies, including trend-following, mean reversion, and momentum plays, optimized for different timeframes from intraday to long-term holds. Performance metrics such as win rate, average return, and Sharpe ratio highlight their edge, with filters allowing users to select bots relevant to specific tickers like GKOS or sectors like healthcare. Updated in real-time, the section emphasizes transparency and backtested results to aid informed trading decisions. Explore Trending AI Robots today to integrate cutting-edge automation into your stock analysis and portfolio strategy.
GKOS Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring GKOS should track upcoming Q1 2026 earnings for updates on Epioxa uptake, glaucoma platform growth, and 2026 guidance reaffirmation. Continued J-code implementation and payer adoption for new therapies will influence reimbursement dynamics. Industry trends in ophthalmology, including regulatory approvals for pipeline candidates and competitive launches in corneal and retinal spaces, remain key. Macro environment factors like healthcare policy shifts and medtech funding trends could impact sentiment. Strategic developments such as international expansion and potential partnerships warrant attention, alongside risks from execution delays or sector headwinds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
GKOS in upward trend: price expected to rise as it breaks its lower Bollinger Band on May 22, 2026
GKOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where GKOS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GKOS's RSI Indicator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 08, 2026. You may want to consider a long position or call options on GKOS as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on June 09, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
GKOS moved below its 50-day moving average on June 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GKOS crossed bearishly below the 50-day moving average on June 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.881) is normal, around the industry mean (10.935). P/E Ratio (0.000) is within average values for comparable stocks, (62.490). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.721). GKOS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (12.970) is also within normal values, averaging (24.020).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices